Circulatory factors associated with function and prognosis in patients with severe heart failure.
Multiplex immunoassay
New york heart association (NYHA) functional classification
Orthogonal projections to latent structures discriminant analysis (OPLS-DA)
Principal component analysis (PCA)
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
08
11
2018
accepted:
13
09
2019
pubmed:
29
9
2019
medline:
4
3
2021
entrez:
29
9
2019
Statut:
ppublish
Résumé
Multiple circulatory factors are increased in heart failure (HF). Many have been linked to cardiac and/or skeletal muscle tissue processes, which in turn might influence physical activity and/or capacity during HF. This study aimed to provide a better understanding of the mechanisms linking HF with the loss of peripheral function. Physical capacity measured by maximum oxygen uptake, myocardial function (measured by echocardiography), physical activity (measured by accelerometry), and mortality data was collected for patients with severe symptomatic heart failure an ejection fraction < 35% (n = 66) and controls (n = 28). Plasma circulatory factors were quantified using a multiplex immunoassay. Multivariate (orthogonal projections to latent structures discriminant analysis) and univariate analyses identified many factors that differed significantly between HF and control subjects, mainly involving biological functions related to cell growth and cell adhesion, extracellular matrix organization, angiogenesis, and inflammation. Then, using principal component analysis, links between circulatory factors and physical capacity, daily physical activity, and myocardial function were identified. A subset of ten biomarkers differentially expressed in patients with HF vs controls covaried with physical capacity, daily physical activity, and myocardial function; eight of these also carried prognostic value. These included established plasma biomarkers of HF, such as NT-proBNP and ST2 along with recently identified factors such as GDF15, IGFBP7, and TfR, as well as a new factor, galectin-4. These findings reinforce the importance of systemic circulatory factors linked to hemodynamic stress responses and inflammation in the pathogenesis and progress of HF disease. They also support established biomarkers for HF and suggest new plausible markers.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple circulatory factors are increased in heart failure (HF). Many have been linked to cardiac and/or skeletal muscle tissue processes, which in turn might influence physical activity and/or capacity during HF. This study aimed to provide a better understanding of the mechanisms linking HF with the loss of peripheral function.
METHODS AND RESULTS
RESULTS
Physical capacity measured by maximum oxygen uptake, myocardial function (measured by echocardiography), physical activity (measured by accelerometry), and mortality data was collected for patients with severe symptomatic heart failure an ejection fraction < 35% (n = 66) and controls (n = 28). Plasma circulatory factors were quantified using a multiplex immunoassay. Multivariate (orthogonal projections to latent structures discriminant analysis) and univariate analyses identified many factors that differed significantly between HF and control subjects, mainly involving biological functions related to cell growth and cell adhesion, extracellular matrix organization, angiogenesis, and inflammation. Then, using principal component analysis, links between circulatory factors and physical capacity, daily physical activity, and myocardial function were identified. A subset of ten biomarkers differentially expressed in patients with HF vs controls covaried with physical capacity, daily physical activity, and myocardial function; eight of these also carried prognostic value. These included established plasma biomarkers of HF, such as NT-proBNP and ST2 along with recently identified factors such as GDF15, IGFBP7, and TfR, as well as a new factor, galectin-4.
CONCLUSIONS
CONCLUSIONS
These findings reinforce the importance of systemic circulatory factors linked to hemodynamic stress responses and inflammation in the pathogenesis and progress of HF disease. They also support established biomarkers for HF and suggest new plausible markers.
Identifiants
pubmed: 31562542
doi: 10.1007/s00392-019-01554-3
pii: 10.1007/s00392-019-01554-3
pmc: PMC7239817
doi:
Substances chimiques
Biomarkers
0
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
655-672Références
J Am Coll Cardiol. 2011 Jul 26;58(5):474-80
pubmed: 21777743
J Proteome Res. 2015 Aug 7;14(8):3322-35
pubmed: 26088811
Am J Cardiol. 2014 Nov 15;114(10):1543-9
pubmed: 25248814
Nucleic Acids Res. 2011 Aug;39(15):e102
pubmed: 21646338
Eur J Heart Fail. 2012 Nov;14(11):1249-56
pubmed: 22843564
Curr Opin Rheumatol. 2001 Nov;13(6):483-7
pubmed: 11698724
Am J Cardiol. 2015 Apr 2;115(7 Suppl):64B-9B
pubmed: 25665758
BMJ. 2015 Mar 04;350:h910
pubmed: 25740799
Protein Cell. 2016 May;7(5):314-24
pubmed: 27017379
Circulation. 1997 Jun 17;95(12):2660-7
pubmed: 9193435
Jpn Heart J. 2003 Sep;44(5):725-34
pubmed: 14587654
Heart Fail Rev. 2013 Jan;18(1):79-94
pubmed: 22733204
Am J Cardiol. 2001 Oct 1;88(7):805-8
pubmed: 11589856
Kardiol Pol. 2008 Feb;66(2):144-51; discussion 152-3
pubmed: 18344152
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
JACC Heart Fail. 2016 Nov;4(11):860-869
pubmed: 27744089
Am J Cardiol. 2015 Apr 2;115(7 Suppl):38B-43B
pubmed: 25697917
Circ Heart Fail. 2011 Mar;4(2):180-7
pubmed: 21178018
Compr Physiol. 2015 Dec 15;6(1):187-214
pubmed: 26756631
Cell Oncol (Dordr). 2013 Feb;36(1):9-13
pubmed: 23117840
Eur Heart J. 2013 May;34(19):1404-13
pubmed: 23095984
Eur J Heart Fail. 2012 Dec;14(12):1338-47
pubmed: 22869458
Clin Chem. 2013 Jul;59(7):1091-8
pubmed: 23529704
PLoS One. 2016 Apr 07;11(4):e0153036
pubmed: 27054323
Circulation. 2010 Oct 5;122(14):1387-95
pubmed: 20855664
JACC Heart Fail. 2013 Feb;1(1):1-20
pubmed: 24621794
Eur J Heart Fail. 2015 Nov;17(11):1133-43
pubmed: 26333529
Front Immunol. 2017 Apr 24;8:475
pubmed: 28484466
Genome Med. 2014 Aug 09;6(8):59
pubmed: 25228925
PLoS One. 2008 Jul 09;3(7):e2629
pubmed: 18612433
Eur J Heart Fail. 2014 Sep;16(9):929-41
pubmed: 25175894
Circ Heart Fail. 2014 May;7(3):418-26
pubmed: 24622243
Circ Res. 2006 Feb 17;98(3):294-7
pubmed: 16484622
Curr Cardiol Rev. 2016;12(1):37-46
pubmed: 26750722
Int Heart J. 2005 Nov;46(6):1049-59
pubmed: 16394601
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2032-42
pubmed: 16123323
N Engl J Med. 2008 May 15;358(20):2148-59
pubmed: 18480207
J Am Coll Cardiol. 2014 Oct 28;64(17):1765-74
pubmed: 25443696
J Am Coll Cardiol. 2008 Oct 28;52(18):1458-65
pubmed: 19017513
J Clin Endocrinol Metab. 1993 Feb;76(2):343-6
pubmed: 8432776
Nat Rev Immunol. 2016 Apr;16(4):204
pubmed: 26972726
Prev Chronic Dis. 2012;9:E113
pubmed: 22698174
Shock. 2005 Jun;23(6):543-8
pubmed: 15897808
J Card Fail. 2016 Jul;22(7):492-7
pubmed: 26844765
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Eur J Prev Cardiol. 2017 May;24(8):808-817
pubmed: 28134562
PLoS One. 2012;7(6):e37696
pubmed: 22719846
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Can J Cardiol. 2015 Jun;31(6):792-9
pubmed: 26022990
Eur Heart J. 2014 Jan;35(1):16-24
pubmed: 24216390
Cancer Sci. 2014 Nov;105(11):1510-7
pubmed: 25230111
Bioinformatics. 2016 Jul 15;32(14):2233-5
pubmed: 27153652
Circulation. 2014 Nov 18;130(21):1847-58
pubmed: 25294786
Circulation. 1991 Mar;83(3):778-86
pubmed: 1999029
J Am Coll Cardiol. 2007 Sep 11;50(11):1054-60
pubmed: 17825714
Scand J Clin Lab Invest Suppl. 1999;230:132-42
pubmed: 10389212
J Nutr Biochem. 2006 Aug;17(8):501-8
pubmed: 16517142
J Card Fail. 2013 Sep;19(9):635-40
pubmed: 24054340
Eur J Heart Fail. 2016 Jan;18(1):81-8
pubmed: 26497848
J Cachexia Sarcopenia Muscle. 2016 Sep;7(4):436-48
pubmed: 27239406
Nat Rev Cardiol. 2017 Jan;14(1):30-38
pubmed: 27708278
Int J Cardiol. 2003 Jan;87(1):83-90
pubmed: 12468058
Int J Cardiol. 2015 Jul 15;191:256-64
pubmed: 25981363
Am J Cardiol. 2016 Jan 1;117(1):116-20
pubmed: 26546248
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239
pubmed: 23747642
Proteomics. 2013 Aug;13(15):2324-34
pubmed: 23713052
J Am Coll Cardiol. 2018 Sep 4;72(10):1081-1090
pubmed: 30165978
Thorax. 2015 Mar;70(3):219-28
pubmed: 25516419
Respir Res. 2001;2(5):269-72
pubmed: 11686894
JACC Heart Fail. 2014 Jun;2(3):260-8
pubmed: 24952693
Circ Heart Fail. 2014 Mar 1;7(2):279-87
pubmed: 24519908
Eur Heart J. 2006 Apr;27(7):832-8
pubmed: 16464912
Immunity. 2004 Jun;20(6):681-93
pubmed: 15189734
Clin Endocrinol (Oxf). 1997 Sep;47(3):287-96
pubmed: 9373449
Circulation. 2006 Mar 21;113(11):1424-33
pubmed: 16534009
EMBO Mol Med. 2017 Aug;9(8):1150-1164
pubmed: 28572090
Mol Cell Biol. 2000 May;20(10):3742-51
pubmed: 10779363
J Cardiovasc Transl Res. 2014 Mar;7(2):250-61
pubmed: 24309956
Curr Opin Hematol. 2015 May;22(3):193-8
pubmed: 25767952
Nat Med. 2007 Nov;13(11):1333-40
pubmed: 17982462
Circ Heart Fail. 2012 Sep 1;5(5):579-85
pubmed: 22773109
J Am Heart Assoc. 2019 Feb 19;8(4):e009555
pubmed: 30760105
Congest Heart Fail. 2011 May-Jun;17(3):110-4
pubmed: 21609383